← Human Trials & Peer-Reviewed Studies
Effect of recombinant growth hormone treatment on children with Crohn's disease and short stature: a pilot study.
Plain-language guide to PMID 15867582 (2005): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 6 boys.
Key Facts
- PMID
- 15867582
- Journal
- Inflammatory bowel diseases
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Calenda KA et al. (4 authors)
- DOI
- 10.1097/01.mib.0000159321.58773.a6
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
Growth failure frequently complicates Crohn's disease in childhood.
Abnormalities in the growth hormone (GH)/insulin-like growth factor-1 axis may occur.
Who Took Part
The study group was 6 boys.
By PubMed's age tags, the people studied were children and teenagers, both men and women.
Seven children (6 boys and 1 girl; age, 11.9-16 yr) with Crohn's disease and growth failure were enrolled.
How the Study Was Run
The design is described as randomized, placebo-controlled and pilot.
The boys were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.
It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.
What Was Measured
PubMed files the paper under topics including Body Height, Crohn Disease, Growth Disorders, Human Growth Hormone, Pilot Projects and Recombinant Proteins.
What This Means in Plain Language
The paper is a randomized, placebo-controlled and pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 6 boys.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2005 (Inflammatory bowel diseases), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.